Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more
Soleno Therapeutics Inc (SLNO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.108x
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has a cash flow conversion efficiency ratio of 0.108x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($48.70 Million) by net assets ($450.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Soleno Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Soleno Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Soleno Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yamada Holdings Co. Ltd
PINK:YMDAF
|
0.019x |
|
Titan Cement International S.A.
PINK:TTCIF
|
0.089x |
|
Dialog Group Bhd
KLSE:7277
|
0.026x |
|
Intershop Holding AG
SW:ISN
|
0.014x |
|
Werner Enterprises Inc
NASDAQ:WERN
|
0.032x |
|
Hangzhou Shunwang Tech
SHE:300113
|
0.046x |
|
Genmab AS
NASDAQ:GMAB
|
0.051x |
|
NORTH PACIFIC BANK LTD
F:2PT
|
N/A |
Annual Cash Flow Conversion Efficiency for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Soleno Therapeutics Inc from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $450.12 Million | $46.80 Million | 0.104x | +136.88% |
| 2024-12-31 | $245.11 Million | $-69.10 Million | -0.282x | -78.03% |
| 2023-12-31 | $157.51 Million | $-24.94 Million | -0.158x | +92.12% |
| 2022-12-31 | $10.35 Million | $-20.78 Million | -2.008x | -28.67% |
| 2021-12-31 | $17.79 Million | $-27.77 Million | -1.561x | -181.82% |
| 2020-12-31 | $45.55 Million | $-25.22 Million | -0.554x | +52.36% |
| 2019-12-31 | $14.95 Million | $-17.38 Million | -1.162x | -202.60% |
| 2018-12-31 | $30.41 Million | $-11.68 Million | -0.384x | -2.45% |
| 2017-12-31 | $26.53 Million | $-9.95 Million | -0.375x | +90.46% |
| 2016-12-31 | $3.44 Million | $-13.50 Million | -3.929x | -22.99% |
| 2015-12-31 | $3.22 Million | $-10.30 Million | -3.195x | -836.12% |
| 2014-12-31 | $-10.33 Million | $-4.48 Million | 0.434x | +1756.41% |
| 2013-12-31 | $-37.86 Million | $-885.22K | 0.023x | -77.14% |
| 2012-12-31 | $-34.20 Million | $-3.50 Million | 0.102x | -- |